What question did this study set out to answer?

The research aims to explore whether bioelectromagnetic modalities can reprogram tumor-immune metabolism to enhance the selective destruction of non-small cell lung cancer (NSCLC).

April 5, 2026

Abstract 7793: Bioelectromagnetic reprogramming of tumor-immune metabolism to selectively destroy NSCLC

Key Points

The research aims to explore whether bioelectromagnetic modalities can reprogram tumor-immune metabolism to enhance the selective destruction of non-small cell lung cancer (NSCLC).
Engineered a device to deliver static EMFs for over six hours daily.
Used human NSCLC xenografts and syngeneic tumors in mice for experiments.
Evaluated tumor growth, survival, and response to chemoradiation therapy.
Conducted mechanistic studies on lipid peroxidation, T-cell activation, and immunological responses.
EMF monotherapy significantly inhibited tumor growth and improved survival rates compared to sham treatment.
EMF treatment increased levels of lipid peroxides and DNA damage markers, indicating tumor cell death.
Enhanced T-cell activation and reduced exhaustion were observed in EMF-treated tumors.
Genetic scavenging in tumors diminished EMF-induced tumor killing, confirming safety and efficacy.

Abstract

Abstract BACKGROUND: Dysregulated oxygen and redox-active metal metabolism create an oxidized tumor microenvironment in non-small cell lung cancer (NSCLC). Tumors accumulate reactive oxygen species (ROS) and labile iron, promoting progression yet creating a vulnerability to iron-catalyzed ROS and lipid peroxidation. This oxidized microenvironment also alters tumor-immune metabolic balance, impeding immune function in the TME. Existing electromagnetic-based therapies such as tumor treating fields and electroporation do not directly target redox-metabolic vulnerabilities and have usability constraints. Building on our recent work published in Cell Metabolism showing that orthogonally applied static electromagnetic fields (EMFs) safely reprogram redox and glucose metabolism to treat diabetes, we sought to determine whether a bioelectromagnetic modality applied during convenient treatment times could be engineered to reprogram tumor-immune metabolism for selective killing of NSCLC. METHODS: We engineered a device to deliver orthogonally oriented static EMFs for ≥6 hours / day. Mice bearing human NSCLC xenografts (H1299 Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7793.

اسأل الذكاء الاصطناعي

Bookmark